|Dr. Jason Scott Slakter||CEO, Pres & Director||375.19k||N/A||1958|
|Mr. Samuel Backenroth||Chief Financial Officer and VP of Bus. Devel.||324.12k||N/A||1984|
|Dr. Glenn L. Stoller M.D.||Chief Scientific Officer||N/A||N/A||1964|
|Dr. Peter K. Kaiser M.D.||Head of Product Devel.||N/A||N/A||N/A|
|Dr. Marlene Modi Ph.D.||Head of Preclinical and Regulatory Affairs||N/A||N/A||N/A|
OHR Pharmaceutical, Inc., a clinical-stage pharmaceutical company, focuses on the development of novel therapies for the treatment of ophthalmic diseases. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes. The company is evaluating Squalamine in combination with Lucentis injections, which completed Phase II clinical trials for the treatment of retinal diseases, including wet form of age-related macular degeneration, retinal vein occlusion, and diabetic retinopathy. It is also developing a sustained release ocular drug delivery platform technology. OHR Pharmaceutical, Inc. is headquartered in New York, New York.
OHR Pharmaceutical, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.